余兆松 - 長庚大學生化暨分子生物學科

跳到主要內容區

系所連結

醫學院

醫學系

生物醫學研究所

行政專區

教育訓練資訊網

余兆松

余兆松
職稱：教授兼分子醫學研究中心主任		研究室名稱：蛋白質體學與疾病生物標識研究室
最高學歷：Ph.D.		學校/國家：國立清華大學/中華民國
分機號碼：5171		電子郵件帳號： yusong@mail.cgu.edu.tw
個人網頁網址：http://yusong1.wix.com/jsyu-lab
研究室現有：博士後研究員 3 人		博士班研究生 2 人		碩士班研究生 2 人
專任研究助理 4 人	大學部專題生 2 人		updated at 2021/9/9
研究方向： (1)以整合性體學研究模式研發口腔癌早期診斷生物標記及精準治療標靶口腔癌為國人好發癌症之一，男性發生率世界第一，已成為國人重大健康議題與醫療負擔。然而在過去二十年間，口腔癌的早期偵測與精準標靶治療進展非常有限，目前仍無有效的生物標記(biomarker)可應用於提高早期口腔癌檢出率及輔助術後追蹤，也缺乏針對口腔癌研發的標靶治療(target therapy)策略以提升個人化的治療效果。本實驗室帶領分子醫學研究中心研究團隊，參與美國領導的國際癌症蛋白基因體聯盟(國際癌症登月計畫的一重要部分)，利用分子醫學研究中心已建置成熟的多體學(multi-omics)分析技術平台，系統性深入研究國人口腔癌(病患癌組織與癌旁非腫瘤組織)的基因體(全外顯子體及RNA定序)、蛋白體(定量蛋白體及磷酸化蛋白體)與代謝體(定量代謝體)全貌及其相關變異，透過整合性體學大數據分析以瞭解基因體變異所造成的蛋白體/代謝體變化，希望建構首個口腔癌 “多體學藍圖”(基因體→蛋白體→代謝體)，提供探索這些系統性變異對口腔癌發生進展的生物意義；同時結合標靶基因/蛋白質/代謝物定量技術及人源化腫瘤動物模式，研發可應用於作為早期偵測之生物標記與精準醫療用藥標靶或指引。 (2)利用先進蛋白質體學分析技術研發可臨床應用之癌症生物標記癌症為人類主要死因之一。大部份癌症被診斷時皆為晚期，是癌症死亡率居高不下的主因。除了養成健康生活習慣外，早期診斷與有效治療是目前對抗癌症的唯一有效方法。雖然有效的癌症生物標記(biomarker)並不多，抽取體液(血液、尿液、唾液等)檢查其中可能的癌症生物標記仍是最方便的初步篩檢方法。因此，找尋新穎且更為有效的體液生物標記是對早期診斷癌症非常重要的課題。以質譜學為基礎之蛋白質體學為近年來新興學門，由於具備高靈敏度、高精確度與高通量之特性，被學界寄予厚望可以用來系統性分析(包括定性與定量)癌症相關樣本中蛋白質，藉以找尋與驗證具高應用價值的癌症生物標記。本實驗室與本校多位同仁合作，共同建立長庚大學蛋白質體學核心實驗室，發展多種蛋白質體相關定性與定量分析技術平台，分別利用三種生物材料(癌症病患組織、體液及癌細胞株)找尋癌症生物標記及分析癌症之異常分子調節機轉。本實驗室目前針對國人數種好發癌症，包括口腔癌、大腸癌、肝癌及胰臟癌同步進行研究，長期目標在於發展出可實際應用於臨床偵測早期癌症及其復發的體液生物標記，同時發展可快速方便檢驗這些生物標記的方法。目前口腔癌唾液生物標記的主要研究成果已於2016/10發表，領先其他國際團隊，已獲多國專利，並技術移轉給本土新創生技公司，進行後續免疫檢測試劑開發(ELISA及試紙型快篩)與臨床試驗，此產學合作成果亦獲得生技相關獎項的肯定，包括「2019臺北生技獎-技轉合作獎項優等獎」(2019/07)、「108年度科技部法人鏈結產學合作成果績優案源獎第一名」(2019/11)、「國研院研發服務平台亮點成果獎」(2021/08) 及合作新創生技公司獲「第16屆國家新創獎-初創企業獎」(2019/12)。該ELISA試劑組已於2020/12/04完成歐盟註冊 (註冊號00159706)，產品已可以進入歐盟銷售。此為國人自行成功開發的第一個口腔癌生物標記免疫檢測商品化試劑組，可為後續一系列衍生或相關檢測產品重要參考品，具指標性意義，對提升防治國人口腔癌的檢測能力預期將有重大影響。而胰臟癌血液生物標記的主要研究成果也已於2011/05發表，亦獲多國專利及技術移轉給本土新創生技公司，進行後續免疫檢測試劑開發與臨床試驗。 (3)研發重要醫用或研究用蛋白質的核酸適體(Aptamer) 核酸適體(Aptamer)是具有獨特立體結構的單鏈RNA或DNA(長度在20～80個鹼基)、可與特定分子標靶以構型互補模式結合，此結合作用與抗體--抗原反應類似，因此核酸適體具有發展成為與抗體類似的拮抗劑或分子靶向工具的高應用潛能。本實驗室已建立以PCR為基礎的核酸適體的高效篩選技術SELEX（systematic evolution of ligands by exponential enrichment），將針對重要醫用或研究用蛋白質開發高親和力核酸適體，提供研發疾病檢測或標靶治療的新穎分子工具。 (4)應用蛋白質體學技術研究細胞訊息傳遞分子機制本實驗室以累積多年之蛋白質酵素分離純化鑑定經驗，過去十多年中投入並成功研發以質譜學為基礎之多種蛋白質體相關定性與定量分析技術。利用這些強大效能蛋白質體分析工具，我們可以重新擴大研究檢視各種細胞內關鍵訊息傳導路徑、發現新穎蛋白質交互作用及分析各種蛋白質後轉譯修飾作用，這些可能性大幅提升了細胞生物學領域研究的廣度與深度。
最近五年所發表論文：corresponding author 1. Wu CC#, Lu YT#, Yeh TS#, Chan YH, Dash S, Yu JS (2021) Fucosylated SERPINA1 is a novel serum marker for pancreatic cancer revealed by lectin affinity capture coupled with iTRAQ-based quantitative glycoproteomics approach. Int J Mol Sci 2021 Jun 4; 22(11), 6079. doi: 10.3390/ijms22116079. [PubMed] 2. ● Liu JC, Chen YT, Hsieh YJ, Wu CC, Huang MC, Hsu YC, Wu CT, Chen CK, Dash S, Yu JS* (2021) Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses. Scientific Reports 2021 May 5;11(1):9583. doi: 10.1038/s41598-021-89089-4. [PubMed] 3. Chiang SF⁺, Huang HH⁺, Tsai WS⁺, Tan BCM, Yang CY, Huang PJ, Chang IYF, Lin J, Lu PS, Chin E, Liu YH, Yu JS, Chiang JM, Hung HY, You JF, Liu H. (2021) Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. Biomedical Journal* Available online 16 March 2021. doi: 10.1016/j.bj.2021.03.001 4. Wu CP, Hung CY, Lusvarghi S, Chang YF, Hsiao SH, Huang YH, Hung TH, Yu JS, Ambudkar SV (2021) Overexpression of human ABCB1 and ABCG2 reduces the susceptibility of cancer cells to the histone deacetylase 6-specific inhibitor citarinostat. Int J Mol Sci* 2021 Mar 5; 22(5), 2592. doi: 10.3390/ijms22052592. [PubMed] 5. Liu CC#, Yang YH#, Hsiao YC, Wang PJ, Liu JC, Liu CH, Hsieh WC, Lin CC, Yu JS* (2021) Rapid and efficient enrichment of snake venoms from human plasma by a strong cation exchange tip column to improve snakebite diagnosis. Toxins 2021 Feb 13; 13(2), 140. doi: 10.3390/toxins13020140. [PubMed] 6. ●● Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IYF, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS. (2020) Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer. Cancers (Basel). 2020 Aug 13; 12(8):E2273. doi: 10.3390/cancers12082273. [PubMed] 7. Chen YT^#, Chang IYF^#, Kan CH, Liu YH, Kuo YP, Tseng HH, Chen HC, Liu H, Chang YS, Yu JS, Chang KP, Tan BCM. circRNAome profiling unveils a novel oncogenic circFLNB circuit in oral cancer. (2020) Cells. 2020 Aug 10; 9(8):E1868. doi: 10.3390/cells9081868 [PubMed] 8. ● Lin YH, Wu CC, Su WT, Tseng PC, Hsueh YY, Hsiao YC, Chang KP, Yu JS, Chuang YR. (2020) Target peptide enrichment microfluidic chip for rapid detection of oral squamous cell carcinoma using stable isotope standards and capture by anti-peptide antibodies. Sensors and Actuators B: Chemical** 2020 Nov 1, 322:128607 9. Wu CP, Hung CY, Lusvarghi S, Huang YH, Tseng PJ, Hung TH, Yu JS, Ambudkar SV. (2020) Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology* 2020 Jul 4:114137. doi: 10.1016/j.bcp.2020.114137. [PubMed] 10. Hsueh PC, Wu KA, Yang CY, Hsu CW, Wang CL, Hung CM, Chen YT, Yu JS, Wu CC* (2020) Metabolomic profiling of parapneumonic effusion reveals a regulatory role of dipeptides in interleukin-8 production in neutrophil-like cells. Analytica Chimica Acta 2020 Sep 1;1128:238-250. doi: 10.1016/j.aca.2020.06.022. [PubMed] 11. Chakraborty A, Lin WC, Lin YT, Huang KJ, Wang PY, Chang YF, Wang HI, Ma KT, Wang CY, Huang XR, Lee YH, Chen BC, Hsieh YJ, Chien KY, Lin TY, Liu JL, Sung LY, Yu JS, Chang YS, Pai LM. (2020) SNAP29 mediates the assembly of histidine-induced CTP synthase filaments in proximity to the cytokeratin network. J Cell Sci* 2020 May 11;133(9):jcs240200. doi: 10.1242/jcs.240200. [PubMed] 12. Hsiao TF#, Wang CL#, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ. (2020) Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. Clin Cancer Res. 2020 Jul 1;26(13):3220-3229. doi: 10.1158/1078-0432.CCR-19-3972. [PubMed] 13. Liu CC#, Chou YS#, Chen CY, Liu KL, Huang GJ, Yu JS, Wu CJ, Liaw GW, Hsieh CH, Chen CK. (2020) Pathogenesis of local necrosis induced by Naja atra venom: Assessment of the neutralization ability of Taiwanese freeze-dried neurotoxic antivenom in animal models. PLOS Neglected Tropical Diseases.* 2020 Feb 7;14(2):e0008054. doi: 10.1371/journal.pntd.0008054. [PubMed] 14. ●● Hsiao YC, Lin SY, Chien KY, Chen SF, Wu CC, Chang YT, Chi LM, Chu LJ, Chiang WF, Chien CY, Chang KP, Chang YS, Yu JS* (2020) An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. Anal Chim Acta 1100:118-130. doi: 10.1016/j.aca.2019.12.006. [PubMed] 15. ● Chi LM#, Hsiao YC#, Chien KY#, Chen SF, Chuang YN, Lin SY, Wang WS, Chang IYF, Yang C, Chu LJ, Chiang WF, Chien CY, Chang YS, Chang KP, Yu JS. (2020) Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. J Proteomics*. 2020 Jan 16;211:103571. doi: 10.1016/j.jprot.2019.103571. [PubMed] 16. Lin WR, Chiang JM, Lim SN, Su MY, Chen TH, Huang SW, Chen CW, Wu RC, Tsai CL, Lin YH, Alison MR, Hsieh SY, Yu JS, Chiu CT, Yeh CT. (2019) Dynamic bioenergetic alterations in colorectal adenomatous polyps and adenocarcinomas. EBioMedicine. 2019 Jun;44:334-345. doi: 10.1016/j.ebiom.2019.05.031. [PubMed] 17. Yu J-S. (2019) From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science. Biomedical Journal 2019 Apr; 42(2), 80-83 doi: 10.1016/j.bj.2019.03.004. (Invited article) [PubMed] 18. Chen Y-T, Tsai C-H, Chen C-L, Yu J-S,* Chang Y-H. (2019) Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics. J. Food Drug Anal.* 2019 Apr; 27(2):387-403. doi: 10.1016/j.jfda.2018.09.005. [PubMed] 19. Chen Y-T, Huang H-C, Hsieh Y-J, Fu S-H, Li L, Chen C-L, Chu L-J, Yu J-S. (2019) Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers. J. Food Drug Anal. 2019 Apr; 27(2): 460-474. doi: 10.1016/ j.jfda.2018.11.008. [PubMed] 20. Chou PH, Liao WC; Tsai KW, Chen KC Yu JS, Chen TW. (2019) TACCO, a database connecting transcriptome alterations, pathway alterations and clinical outcomes in cancers. Scientific Reports 2019 Mar 7;9(1):3877. doi: 10.1038/s41598-019-40629-z. [PubMed] 21. Wang P#, Geng J#, Gao J, Zhao H, Li J, Shi Y, Yang B, Xiao C, Linghu Y, Sun X, Chen X, Hong L, Qin F, Li X, Yu JS, You H, Yuan Z, Zhou D, Johnson RL, Chen L* (2019) Macrophage achieves self-protection against oxidative stress-induced ageing through Mst-Nrf2 axis. Nature Communications 2019 Feb 14;10(1):755. doi: 10.1038/s41467-019-08680-6. [PubMed] 22. Hsu C-W#, Chen Y-T#, Hsieh Y-J, Chang K-P, Hsueh P-C, Yu J-S, Chang Y-S, Li L, Wu C-C (2019) Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma. Anal Chim Acta 2019 Mar 7;1050:113-122. doi: 10.1016/j.aca.2018.10.070. [PubMed] 23. Lin Y-H, Chang H-Y, Wu C-C, Wu C-W, Chang K-P, Yu J-S. (2019). BRAF protein immunoprecipitation, elution, and digestion from cell extract using a microfluidic mixer for mutant BRAF protein quantification by mass spectrometry. Anal. Bioanal. Chem. 2019 Feb;411(5):1085-1094. doi: 10.1007/s00216-018-1536-2. [PubMed] 24. Lee C-C#, Hsieh Y-J#, Chen S-W, Fu S-H, Hsu C-W, Wu C-C, Han W, Li Y, Tao H, Chang Y-S, Yu J-S*, Li L, Chang C-H, Chen Y-T. (2018) Bretschneider solution-induced alterations in the urine metabolome in cardiac surgery patients. Scientific Reports 2018 Dec 11;8(1):17774. [PubMed] 25. ●● Liu C-C#, Yu J-S#, Wang P-J, Hsiao Y-C, Liu C-H, Chen Y-C, Lai P-F, Hsu C-P, Fann W-C, Lin C-C. (2018) Development of sandwich ELISA and lateral flow strip assays for diagnosing clinically significant snakebite in Taiwan. PLOS Neglected Tropical Diseases. 2018 Dec 3;12(12):e0007014. [PubMed] ^#Contributed equally 26. Lin W-C, Chakraborty A, Huang S-C, Wang P-Y, Hsieh Y-J, Chien K-Y, Lee Y-H, Chang C-C, Tang H-Y, Lin Y-T, Tung C-S, Luo J-D, Chen T-W, Lin T-Y, Cheng M-L, Chen Y-T, Yeh C-T; Liu J-L, Sung L-Y, Shiao M-S, Yu J-S, Chang Y-S, Pai L-M. (2018) Histidine-dependent protein methylation is required for compartmentalization of CTP synthase. Cell Reports 2018 Sep 4;24(10):2733-2745.e7. [PubMed] 27. Wu CP, Hsieh YJ, Murakami M, Vahedi S, Hsiao SH, Yeh N, Chou AW, Li YQ, Wu YS, Yu JS, Ambudkar SV. (2018) Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochem Pharmacol.* 2018 Jul 17. 155:316-325. [PubMed] 28. Liu C-C#, Lin C-C#, Hsiao Y-C, Wang P-J, Yu J-S. (2018) Proteomic characterization of six Taiwanese snake venoms: Identification of species-specific proteins and development of a SISCAPA-MRM assay for cobra venom factors. J. Proteomics* 2018 Sep 15, 187:59-68. [PubMed] 29. Huang Y-H, Lin K-H, Yu J-S, Wu T-J, Lee W-C, Chao C-K, Pan T-L, Yeh C-T. (2018) Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Mol. Carcinog.* 2018 Apr 19. 57:1087–1101. [PubMed] 30. Chen C-T, Liu C-C, Yu J-S, Li H-H, Lai M-C. (2018) Integrated omics profiling identifies hypoxia-regulated genes in HCT116 colon cancer cells J. Proteomics* 188:139-151. [PubMed] 31. ● Chu LJ#, Hsiao YC#, Chiang WF#, Tsai CJ, Lin SY, Chang KP, Chien CY, Yu JS. (2018) Use of saliva protein biomarkers for diagnosis of oral cavity cancer. International Journal of Head and Neck Science* June 2018; 2(2): 56-68. (Invited review article) [Link] 32. Tsai C-H,#, Chen Y-T,#, Chang Y-H#, Hsueh C, Liu C-Y, Chang Y-S, Chen C-L, Yu J-S* (2018) Systematic verification of bladder cancer-associated tissue protein biomarker candidates in urine specimens. Oncotraget 2018 Jul 20;9(56):30731-30747. [PubMed] 33. Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, Chen SJ, Chen HC, and Tan BC. (2018) MiR-31-5p-ACOX1 axis enhances tumorigenic fitness in oral squamous cell carcinoma via the promigratory prostaglandin E2. Theranostics* 2018 Jan 1;8(2):486-504. [PubMed] 34. ●● Hsiao YC#, Chu LJ#, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chien CY, Chang KP, Chang YS, and Yu JS. (2018) Variability assessment of 90 salivary proteins in intra-day and inter-day samples from healthy donors by multiple reaction monitoring-mass spectrometry. (2018) Proteomics-Clin Appl.* 2018 Mar;12(2). doi: 10.1002/prca.201700039. [PubMed] 35. Wu CC#, Lin JD#, Chen JT, Chang CM, Weng HF, Hsueh C, Chien HP and Yu JS. (2018) Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery. Oncotarget* 9:12079-12100. [PubMed] 36. Liu CC, You CH, Yu JS, Huang GJ, Liu CH, Wang PJ, and Lin CC. (2017) Analysis of the efficacy of Taiwanese freeze neurotoxic antivenom against Southeast Asian cobra venoms through proteomics and animal model approaches. PLOS Neglected Tropical Disease. 2017 Dec 15;11(12): e0006138. [PubMed] 37. ●● Hsiao Y-C, Chi L-M, Chien K-Y, Chiang W-F, Chen S-F, Chuang Y-N, Lin S-Y, Wu C-C, Chu LJ, Chen Y-T, Chia S-L, Chien C-Y, Chang K-P, Chang Y-S, and Yu J-S. (2017) Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry. Mol. Cell. Proteomics* 2017 Oct;16(10):1829-1849. [PubMed] 38. ●● Chen TW#, Lee CC#, Liu H#, Wu CS#, Pickering CR#, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP, Chang YS. (2017) APOBEC3A is an oral cancer prognostic biomarker in carriers of an APOBEC deletion polymorphism. Nature Communications. 2017 Sep 6;8(1):465. [PubMed] 39. ● Hsiao YC#, Chu LJ#, Chen JT, Yeh TS and Yu JS. (2017) Proteomic profiling of the cancer cell secretome: informing clinical research. Expert Review of Proteomics* (Invited review article) 2017 Sep;14(9):737-756. [PubMed] 40. ●● Peng Y#, Zhang M#, Zheng L#, Liang Q#, Li H#, Chen J-T, Guo H, Yoshina S, Chen Y-Z, Zhao X, Wu X, Liu B, Mitani S, Yu J-S, Ding Xue. (2017) Cysteine protease cathepsin B mediates radiation-induced bystander effects. Nature* 547(7664), 458–462 (27 July 2017) [PubMed] 41. Cheng JC, Tseng CP, Liao MH, Peng CY, Yu JS, Chuang PH, Huang JT, Chen JJW. (2017) Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes. Scientific Reports. 2017 June 30;7:4448. doi:10.1038/s41598-017-04259-7 [PubMed] 42. ● Hsieh Y-J#, Chien K-Y#, Yang I-F, Lee I-N, Wu C-C, Huang T-Y, and Yu J-S (2017) Oxidation of protein-bound methionine in Photofrin-photodynamic therapy-treated human tumor cells explored by methionine-containing peptide enrichment and quantitative proteomics approach. Scientific Reports 2017 May 2;7(1):1370. doi: 10.1038/s41598-017-01409-9. [PubMed] 43. Shao CH, Chen CL, Lin JY, Chen CJ, Fu SH, Chen YT, Chang YS, Yu JS*, Tsui KH, Juo CG, Wu KP. (2017) Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics. Oncotarget. 2017 Mar 21. 2017; 8:38802-38810 doi: 10.18632/oncotarget.16393. [PubMed] 44. Chen Y-T, Chen H-W, Wu C-F, Chu L-J, Chiang W-F, Wu C-C, Yu J-S, Tsai C-H, Liang K-H, Chang Y-S, Wu M, Ou Yang W-T. (2017) Development of a multiplexed LC-MRM/MS method for evaluation of salivary proteins as oral cancer biomarkers. Mol. Cell. Proteomics 2017 May;16(5):799-811. [PubMed] 45. ● Lin YT, Chien KY, Wu CC, Chang WY, Chu LJ, Yeh CT, Yu JS. (2017) Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. J. Proteomics. 2017 Mar 22;157:40-51. [PubMed] 46. Chung I-C, OuYang C-N, Yuan S-N, Li H-P, Chen J-T, Shieh H-R, Chen Y-J, Ojcius DM, Yu J-S, Chang Y-S, Chen L-C. (2016) Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis. Scientific Reports* 2016 Oct 31; 6:36214. [PubMed] 47. ●● Yu JS^#, Chen YT^#, Chiang WF^#, Hsiao YC^#, Chu LJ^#, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Cha SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, Pao CC, Chang YS, Hartwell LH (2016) Saliva Protein Biomarkers to Detect Oral Squamous Cell Carcinoma in a High-Risk Population in Taiwan. Proc Natl Acad Sci USA. 2016 Oct 11;113(41):11549-11554. (^#Co-first authors) [PubMed] 48. Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, Liu CC, Yu JS, Chang YS, Yu CJ.* (2016) Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol. Cell. Proteomics 2016 Jul;15(7):2396-410. [PubMed] 49. ● Chen H#, Hsiao Y-C#, Chiang S-F, Wu C-C, Lin Y-T, Liu H, Zhao H, Chen J-S, Chang Y-S, and Yu J-S. (2016) Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. Anal. Chim.* Acta 2016 Aug 24; 933:144-55. [PubMed] 50. Wang C-I, Chan Y-Y, Wang C-L, Yu J-S, Chang Y-S, and Yu C-J. (2016) mTOR regulates proteasomal degradation and Dp1/E2F1-mediated transcription of KPNA2 in lung cancer cells. Oncotarget* 2016 May 3;7(18):25432-42. [PubMed] 51. Wu C-P, Hsieh Y-J, Hsiao S-H, Su C-Y, Li Y-Q, Huang Y-H, Huang C-W, Hsieh C-H, Yu J-S* and Wu Y-S. (2016) Human ATP-Binding Cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase. Mol. Pharm.* 2016 Mar 7;13(3):784-94. [PubMed] 專利: 1. Yu JS, Chang KP. (2012) Method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker. United States Patent, US8,148,059B2, Apr. 3, 2012. Patent period 2012/4/3~2029/10/30 2. 陳怡婷、余兆松、陳建綸、張玉生 (2013) 膀胱癌之生物標記及其檢測方法。中華民國專利發明第I390204號, 專利權期間: 2013/03/21-2030/2/10 3. 余兆松、張雅婷、吳治慶、石宜銘、張玉生 (2013) 胰臟癌之血清生物檢測標誌及其應用。中華民國專利發明第I408370號, 專利權期間: 2013/9/11~2031/5/18 4. 余兆松、蔡名鴻、謝玲玲 (2014) 大腸直腸癌遠端轉移之血漿生物標誌及其應用。中華民國專利發明第I444386號, 專利權期間: 2014/7/11~2032/4/9 5. Chao-Sung Lai, Jau-Song Yu, Yu-Sun Chang, Po-Lung Yang, Tseng-Fu Lu, Yi-Ting Lin, Wen-Yu Chuang, Ting-Chun Yu, I-Shun Wang, Jyh-Ping Chen, Chou Chien (2014) Surface treatment method by using the NH3 plasma treatment to modify the sensing thin-film. United States Patent, US8741679 B2, June 3, 2014. Patent period 2014/6/3~2032/5/8 6. Jau-Song Yu, Ya-Ting Chang, Chih-Ching Wu, Yi-Ming Shyr, Yu-Sun Chang (2014) A method for detecting pancreatic cancer using the serological marker ULBP2. European patent, EP2525227B1, Patent period: 2/16/2015~5/16/2032 (Poland), 11/19/2014~5/16/2032 (France), 12/11/2014~5/16/2032 (Germany), 1/20/2015~5/16/2032 (Italy), 11/19/2014~5/16/2032 (United Kingdom), 1/13/2015~5/16/2032 (Spain) 7. 陳怡婷、余兆松、陳建綸、張玉生 (2016) 尿液生物標記作為預測膀胱及腎臟癌的用途。中華民國專利發明第I522367號, 專利權期間: 2016/2/21~2033/4/11 8. Jau-Song Yu, Wei-Fan Chiang, Yi-Ting Chen, Yu-Sun Chang, Lai-Chu See, Yung Chin Hsiao, Kai-Ping Chang. (2016) Apparatus and methods for detecting oral squamous cell carcinoma. US provisional application. No. 62309766 (application date: 2016/03/17) 9. Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2017) Methods for cancer diagnosis and prognosis. International application (PCT) No. PCT/US17/22853 (application date: 2017/03/17) 10. 余兆松、陳怡婷、蔣維凡、蕭永晉、張玉生、史麗珠、張凱評 (2019) 一種用以診斷及預斷癌症的方法。中華民國專利發明第I651536號, 專利權期間: 2019/2/21~2037/3/15 11. Err-Cheng Chan, Kuei-Tien Chen, Jau-Song Yu, Yu-Sun Chang Jinn-Shiun Chen. (2017) Serological markers for detecting colorectal cancer and their application for inhibiting colorectal cancer cells. United States Patent, US 9,835,636 B2, Dec. 5, 2017. Patent period: 2011/10/4-2031/10/3 12. Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2020) Methods for cancer diagnosis and prognosis. European patent, EP3430406B1, Patent period: 2020/12/02~2037/3/17. (application date: 2017/03/17; application No.17767588.1) 13. 張雅婷/余兆松/王俊勝/吳淑芳/陳致儒/劉晏君 (2021) 第一型基質金屬蛋白酶的單株抗體、其檢測套組及其檢測方法 (Matrix metalloproteinase-1 monoclonal antibody, detection kit and detection method thereof) 中華民國專利(申請案號：109106582, 申請日2020/02/27)(審定核准日2021/05/14) 技轉與產學合作: 1.「口腔癌檢測方法的相關技術」技轉世延生醫股份有限公司, 2017/1/23-2023/1/22. 產學合作計畫「口腔癌生物標誌免疫檢測試劑開發」, 2017/6/1-2020/12/31. 2.「胰臟癌之血清生物檢測標誌及其應用」技轉世延生醫股份有限公司, 2020/01/10~2030/01/10. 「胰臟癌症生物標誌免疫試劑開發測試」, 2020/9/1-2022/8/31.

瀏覽數:

分享